Prognostic markers and putative therapeutic targets for hepatocellular carcinoma

Molecular Aspects of Medicine

Volumn 31, Issue 2, 2010, Pages 179-193

  Frau, Maddalena ^a   Biasi, Fiorella ^b   Feo, Francesco ^a   Pascale, Rosa M ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Genetic predisposition; Hepatocarcinogenesis; Prognostic markers; Signal transduction; Therapeutic targets

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BEVACIZUMAB; ERLOTINIB; FORKHEAD BOX M1; FORKHEAD TRANSCRIPTION FACTOR; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; IRINOTECAN; MAPATUMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; RAPAMYCIN; RAS PROTEIN; S ADENOSYLMETHIONINE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UO 126;

ADVANCED CANCER; CANCER GROWTH; CANCER PREVENTION; CANCER SURVIVAL; CELL CYCLE REGULATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; GENETIC RESISTANCE; GENETIC SUSCEPTIBILITY; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR INTERACTION; MOLECULAR THERAPY; NONHUMAN; ONCOGENE C MYC; PHENOTYPE; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; LIVER NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

RATTUS; RODENTIA;

EID: 77951429707     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2010.02.007     Document Type: Review

References (124)

1. Abou-Alfa G.K. Hepatocellular carcinoma: molecular biology and therapy. Semin. Oncol. 2006, 33(Suppl. 11):S79-S83.
2. Abou-Alfa, G.K., Amadori, D., Santoro, A., Figer, A., De Greve, J., Lathia, C., Voliotis, D., Anerson, S., Moscovici, M., Ricci, S., 2008. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and child-pugh B (CPB) cirrhosis? J. Clin. Oncol. 26 (May 20 Suppl. abstr. 4518).
3. Arsura M., Cavin L.G. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett. 2005, 229:157-169.
4. Avila M.A., Berasain C., Sangro B., Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006, 25:3866-3884.
5. Bilger A., Bennett L.M., Carabeo R.A., Chiaverotti T.A., Dvorak C., Lis K.M., Schadewald S.A., Pitot H.C., Drinkwater N.R. A potent modifier of liver cancer risk on distal mouse chromosome 1: linkage analysis and characterization of congenic lines. Genetics 2004, 167:859-866.
6. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
7. Branda M., Wands J.R. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 2006, 43:891-902.
8. Bruix J., Boix L., Sala M., Llovet J.M. Focus on hepatocellular carcinoma. Cancer Cell. 2004, 5:215-219.
9. Buendia M.A. Genetics of hepatocellular carcinoma. Semin. Cancer Biol. 2000, 10:185-200.
10. Bulavin D.V., Kovalsky O., Hollander M.C., Fornace A.J. Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a. Mol. Cell. Biol. 2003, 23:3859-3871.
11. Cai R.L., Meng W., Lu H.Y., Lin W.Y., Jiang F., Shen F.M. Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China. World J. Gastroenterol. 2003, 9:2428-2432.
12. Calvisi D.F., Pascale R.M., Feo F. Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev. Recent Clin. Trias 2007, 2:217-236.
13. Calvisi D.F., Simile M.M., Ladu S., Pellegrino R., De Murtas V., Pinna F., Tomasi M.L., Frau M., Virdis P., De Miglio M.R., Muroni M.R., Pascale R.M., Feo F. Altered methionine metabolism and global DNA methylation in liver cancer: relationship with genomic instability and prognosis. Int. J. Cancer 2007, 121:2410-2420.
14. Calvisi D.F., Pinna F., Ladu S., Pellegrino R., Muroni M.R., Simile M.M., Frau M., Tomasi M.L., De Miglio M.R., Seddaiu M.A., Daino L., Sanna V., Feo F., Pascale R.M. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis 2008, 29:1639-1647.
15. Calvisi D.F., Pinna F., Ladu S., Pellegrino R., Sanna V., Sini M., Daino L., Simile M.M., De Miglio M.R., Frau M., Tomasi M.L., Seddaiu M.A., Muroni M.R., Feo F., Pascale R.M. Ras-driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control. Int. J. Cancer 2008, 123:2057-2064.
16. Calvisi D.F., Pinna F., Meloni F., Ladu S., Pellegrino R., Sini M., Daino L., Simile M.M., De Miglio M.R., Virdis P., Frau M., Tomasi M.L., Seddaiu M.A., Muroni M.R., Feo F., Pascale R.M. Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated-kinase-mediated control of growth in human hepatocellular carcinoma. Cancer Res. 2008, 68:4192-4200.
17. Calvisi D.F., Ladu S., Pinna F., Frau M., Tomasi M.L., Sini M., Simile M.M., Bonelli P., Muroni M.R., Seddaiu M.A., Lim D.S., Feo F., Pascale R.M. SKP2 and CKS1 Promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 2009, 137:1816-1826.
18. Calvisi D.F., Pinna F., Ladu S., Pellegrino R., Simile M.M., Frau M., De Miglio M.R., Tomasi M.L., Sanna V., Muroni M.R., Feo F., Pascale R.M. Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut 2009, 58:679-687.
19. Calvisi D.F., Pinna F., Ladu S., Muroni M.R., Frau M., Demartis I., Tomasi M.L., Sini M., Simile M.M., Seddaiu M.A., Feo F., Pascale R.M. The degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase is genetically controlled in rodent liver cancer and contributes to determine the susceptibility to the disease. Int. J. Cancer 2010, 126:1275-1281.
20. Carter S.L., Eklund A.C., Kohane I.S., Harris L.N., Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 2006, 38:1043-1048.
21. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65:6029-6033.
22. Cianchi F., Cortesini C., Fantappiè O., Messerini L., Sardi I., Lasagna N., Perna F., Fabbroni V., Di Felice A., Perigli G., Mazzanti R., Masini E. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin. Cancer Res. 2004, 10:2694-2704.
23. ClinicalTrials.gov identifier: NCT00712855; 2008. A two-stage, multi-center, open label, dose escalation study of mapatumumab ([HGS1012], a fully-human monoclonal antibody to TRAIL-R1) in combination with sorafenib as a first line therapy in subjects with advanced hepatocellular carcinoma.
24. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., Fabre M., Chelly J., Beldjord C., Kahn A., Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA 1998, 95:8847-8851.
25. De Mglio M.R., Muroni M.R., Simile M.M., Virdis P., Asara G., Frau M., Calvisi D.F., Seddaiu M.A., Pascale R.M., Feo F. Frequent loss of heterozygosity at the Hcr1 (hepatocarcinogenesis resistance) locus on chromosome 10 in primary hepatocellular carcinomas from LFF1 rat strain. Hepatology 2001, 33:1110-1117.
26. De Miglio M.R., Simile M.M., Muroni M.R., Pusceddu S., Calvisi D., Carru A., Seddaiu M.A., Daino L., Deiana L., Pascale R.M., Feo F. Correlation of c-myc overexpression and amplification with progression of preneoplastic liver lesions to malignancy in the poorly susceptible Wistar rat strain. Mol. Carcinogen. 1999, 25:21-29.
27. De Miglio M.R., Simile M.M., Muroni M.R., Calvisi D.F., Virdis P., Asara G., Frau M., Bosinco G.M., Seddaiu M.A., Daino L., Feo F., Pascale R.M. Phenotypic reversion of rat neoplastic liver nodules is under genetic control. Int. J. Cancer 2003, 105:70-75.
28. De Miglio M.R., Pascale R.M., Simile M.M., Muroni M.R., Virdis P., Kwong K.M., Wong L.K., Bosinco G.M., Pulina F.R., Calvisi D.F., Frau M., Wood G.A., Archer M.C., Feo F. Polygenic control of hepatocarcinogenesis in Copenhagen×F344 rats. Int. J. Cancer 2004, 111:9-16.
29. Elmén J., Lindow M., Schütz S., Lawrence M., Petri A., Obad S., Lindholm M., Hedtjärn M., Hansen H.F., Berger U., Gullans S., Kearney P., Sarnow P., Straarup E.M., Kauppinen S. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899.
30. Epstein R.J., Leung T.W. Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin. Cancer Res. 2007, 13:11-17.
31. Farazi P.A., De Pinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. 2006, 6:674-687.
32. Farber E., Sarma D.S.R. Hepatocarcinogenesis: a dynamic cellular perspective. Lab. Invest. 1987, 56:4-22.
33. Feo F., Pascale R.M., Simile M.M., De Miglio M.R., Muroni M.R., Calvisi D.F. Genetic alterations in liver carcinogenesis. Curr. Rev. Oncogen. 2000, 11:19-62.
34. Feo F., De Miglio M.R., Simile M.M., Muroni M.R., Calvisi D.F., Frau M., Pascale R.M. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim. Biophys. Acta Cancer Rev. 2006, 176:126-147.
35. Feo, F., Pascale, R.M., Calvisi, D.F., 2007. Models for liver cancer. In: Alison, M.R. (Ed.), The Cancer Handbook, vol. 2. second ed., John Wiley and Sons, Ltd., Chichester, UK, pp. 1118-1133.
36. Feo F., Frau M., Pascale R.M. Interaction of major genes predisposing to hepatocellular carcinoma with genes encoding signal transduction pathways influences tumor phenotype and prognosis. World J. Gastroenterol. 2008, 14:6601-6615.
37. Ferber M.J., Montoya D.P., Yu C., Aderca I., McGee A., Thorland E.C., Nagorney D.M., Gostout B.S., Burgart L.J., Boix L., Bruix J., McMahon B.J., Cheung T.H., Chung T.K., Wong Y.F., Smith D.I., Roberts L.R. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003, 22:3320-3813.
38. Fernandez E., La Vecchia C., D'Avanzo B., Negri E., Franceschi S. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 1994, 3:209-212.
39. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit. Rev. Clin. Lab. Sci. 2000, 3:431-502.
40. Gariboldi M., Pascale R.M., Manenti G., De Miglio M.R., Calvisi D., Carru A., Dragani T.A., Feo F. Analysis of loss of heterozygosity in neoplastic nodules induced by diethylnitrosamine in the resistant BFF1 rat strain. Carcinogenesis 1999, 20:1363-1368.
41. Gaubatz S., Lees J.A., Lindeman G.J., Livingston D.M. E2F4 is exported from the nucleus in a CRM1-dependent manner. Mol. Cell. Biol. 2001, 21:1384-1392.
42. Gómez-Angelats M., Teeguarden J.G., Dragan Y.P., Pitot H.C. Mutational analysis of three tumor suppressor genes in two models of rat hepatocarcinogenesis. Mol. Carcinogen. 1999, 25:157-163.
43. Gramantieri L., Fornari F., Callegari E., Sabbioni S., Lanza G., Croce C.M., Bolondi L., Negrini M. MicroRNAbivolvement in hepatocellular carcinoma. J. Cell. Mol. Med. 2008, 12:2189-2204.
44. Greten F.R., Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004, 206:193-199.
45. Hemminki K., Li X. Familial risks of cancer as a guide to gene identification and mode of inheritance. Int. J. Cancer 2004, 110:291-294.
46. Hers I., Wherlock M., Homma Y., Yagisawa H., Tavare J.M. Identification of p122RhoGAP (deleted in liver cancer-1) serine-322 as a substrate for protein kinase B and RSK in insulin-stimulated cells. J. Biol. Chem. 2006, 281:4762-4770.
47. Hoeller D., Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009, 458:438-454.
48. Hoki Y., Hiraku Y., Ma N., Murata M., Matsumine A., Nagahama M., Shintani K., Uchida A., Kawanishi S. INOS-dependent DNA damage in patients with malignant fibrous histiocytoma in relation to prognosis. Cancer Sci. 2007, 98:163-168.
49. Hu K.-Q. Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J. Lab. Clin. Med. 2002, 139:234-243.
50. Hui L., Bakiri L., Stepniak E., Wagner E.F. P38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 2007, 6:2429-2433.
51. Hussain S.P., Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 2007, 121:2373-2380.
52. Huynh H., Soo K.C., Chow P.K., Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol. Cancer Ther. 2007, 6:138-146.
53. Huynh H., Ngo V.C., Koong H.N., Poon D., Choo S.P., Thng C.H., Chow P., Ong H.S., Chung A., Soo K.C. Sorafenib and Rapamycin Induce Growth Suppression in Mouse Models of Hepatocellular Carcinoma. J. Cell. Mol. Med. 2009, 13:2673-2683.
54. Ieta K., Ojima E., Tanaka F., Nakamura Y., Haraguchi N., Mimori K., Inoue H., Kuwano H., Mori M. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int. J. Cancer 2007, 121:33-38.
55. Ikeguchi M., Ueta T., Yamane Y., Hirooka Y., Kaibara N. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin. Cancer Res. 2002, 8:3131-3136.
56. Inoue T., Shiraki K., Fuke H., Yamanaka Y., Miyashita K., Yamaguchi Y., Yamamoto N., Ito K., Sugimoto K., Nakano T. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs 2006, 17:261-268.
57. Jüngst C., Cheng B., Gehrke R., Schmitz V., Nischalke H.D., Ramakers J., Schramel P., Schirmacher P., Sauerbruch T., Caselmann W.H. Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology 2004, 39:1663-1672.
58. Kaposi-Novak P., Libbrecht L., Woo H.G., Lee Y.H., Sears N.C., Coulouarn C., Conner E.A., Factor V.M., Roskams T., Thorgeirsson S.S. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 2009, 69:2775-2782.
59. Kawanishi S., Hiraku Y., Pinlaor S., Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol. Chem. 2006, 387:365-372.
60. Kern M.A., Breuhahn K., Schirmacher P. Molecular pathogenesis of human hepatocellular carcinoma. Adv. Cancer Res. 2002, 86:67-112.
61. Kim I.M., Ackerson T., Ramakrishna S., Tretiakova M., Wang I.C., Kalin T.V., Major M.L., Gusarova G.A., Yoder H.M., Costa R.H., Kalinichenko V.V. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 2006, 66:2153-2161.
62. Kimura H., Esumi H. Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim. Pol. 2003, 50:49-59.
63. Kuo M.T., Liu Z., Wei Y., Lin-Lee Y.C., Tatebe S., Mills G.B., Unate H. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kB signaling. Oncogene 2002, 21:1945-1954.
64. Laoukili J., Kooistra M.R., Brás A., Kauw J., Kerkhoven R.M., Morrison A., Clevers H., Medema R.H. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 2005, 7:126-136.
65. Lavoie J.N., L'Allemain G., Brunet A., Müller R., Pouysségur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 1996, 271:20608-20616.
66. Lee J.S., Thorgeirsson S.S. Comparative and integrative functional genomics of HCC. Oncogene 2006, 25:3801-3809.
67. Li L.G., Xu H.H. Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. World J. Gastroenterol. 2005, 11:2539-2544.
68. Lin Y.W., Yang J.L. Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferating signaling. J. Biol. Chem. 2006, 281:915-926.
69. Lin Z.Z., Hsu H.C., Hsu C.H., Yeh P.Y., Huang C.Y., Huang Y.F., Chen T.J., Kuo S.H., Hsu C., Hu F.C., Jeng Y.M., Chung Y., Cheng A.L. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J. Hepatol. 2009, 50:518-527.
70. Liu R.M., Gaston Pravia K.A. Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. Free Radic. Biol. Med. 2010, 48:1-15.
71. Liu H., Higashi K., Hiai H.P. Role of resistant Drh1 locus in chemical carcinogen-induced hepatocarcinogenesis in rats: analysis with a speed congenic strain. Cancer Sci. 2005, 96:164-169.
72. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
73. Lu S.C. Antioxidants in the treatment of chronic liver diseases: why is the efficacy evidence so weak in humans?. Hepatology 2008, 48:1359-1361.
74. Mann C.D., Neal C.P., Garcea G., Manson M.M., Dennison A.R., Berry D.P. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur. J. Cancer. 2007, 43:979-992.
75. Marshall C. How do small GTPase signal transduction pathways regulate cell cycle entry?. Curr. Opin. Cell Biol. 1999, 11:732-736.
76. Mato J.M., Lu S.C. Role of S-adenosyl-l-methionine in liver health and injury. Hepatology 2007, 45:1306-1312.
77. Matsuzaki K., Murata M., Yoshida K., Sekimoto G., Uemura Y., Sakaida N., Kaibori M., Kamiyama Y., Nishizawa M., Fujisawa J., Okazaki K., Seki T. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007, 46:48-57.
78. Melhem M.F., Kunz H.W., Gill T.J. A major histocompatibility complex-linked locus in the rat critically influences resistance to diethylnitrosamine carcinogenesis. Proc. Natl. Acad. Sci. USA 1993, 90:1967-1971.
79. Mínguez B., Tovar V., Chiang D., Villanueva A., Llovet J.M. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr. Opin. Gastroenterol. 2009, 25:186-194.
80. Miyashita K., Shiraki K., Fuke H., Inoue T., Yamanaka Y., Yamaguchi Y., Yamamoto N., Ito K., Sugimoto K., Nakano T. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int. J. Mol. Med. 2006, 18:249-256.
81. Nagata H., Hatano E., Tada M., Murata M., Kitamura K., Asechi H., Narita M., Yanagida A., Tamaki N., Yagi S., Ikai I., Matsuzaki K., Uemoto S. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma. Hepatology 2009, 49:1944-1953.
82. Newell P., Toffanin S., Villanueva A., Chiang D.Y., Minguez B., Cabellos L., Savic R., Hoshida Y., Lim K.H., Melgar-Lesmes P., Yea S., Peix J., Deniz K., Fiel M.I., Thung S., Alsinet C., Tovar V., Mazzaferro V., Bruix J., Roayaie S., Schwartz M., Friedman S.L., Llovet J.M. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J. Hepatol. 2009, 51:725-733.
83. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
84. Pang R., Yuen J., Yuen M.F., Lai C.L., Lee T.K., Man K., Poon R.T., Fan S.T., Wong C.M., Ng I.O., Kwong Y.L., Tse E. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 2004, 23:4182-4186.
85. Pascale R.M., Marras V., Simile M.M., Daino L., Pinna G., Bennati S., Carta M., Seddaiu M.A., Massarelli G., Feo F. Chemoprevention of rat liver carcinogenesis by S-adenosyl-l-methionine: a long-term study. Cancer Res. 1992, 52:4979-4986.
86. Pascale R.M., Simile M.M., Feo F. Genomic abnormalities in hepatocarcinogenesis. Implications for a chemopreventive strategy. Anticancer Res. 1993, 13:1341-1356.
87. Pascale R.M., Simile M.M., De Miglio M.R., Nufris A., Daino L., Seddaiu M.A., Rao P.M., Rajalakshmi S., Sarma D.S.R., Feo F. Chemoprevention by S-adenosyl-l-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis 1995, 16:427-430.
88. Pascale R.M., Simile M.M., De Miglio M.R., Nufris A., Seddaiu M.A., Muroni M.R., Danni O., Rao K.N., Feo F. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase activity and gene expression by dehydrocpiandrosterone in preneoplastic liver nodules. Carcinogenesis 1995, 16:1537-1542.
89. Pascale R.M., De Miglio M.R., Muroni M.R., Simile M.M., Daino L., Seddaiu M.A., Nufris A., Gaspa L., Deiana L., Feo F. C-myc amplification in pre-malignant and malignant lesions induced in rat liver by the resistant hepatocyte model. Int. J. Cancer 1996, 68:136-142.
90. Pascale R.M., Simile M.M., De Miglio M.R., Muroni M.R., Calvisi D.F., Asara G., Casabona D., Frau M., Seddaiu M.A., Feo F. Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis. Hepatology 2002, 35:1341-1350.
91. Pascale R.M., Simile M.M., Calvisi D.F., Frau M., Muroni M.R., Seddaiu M.A., Daino L., Muntoni M.D., De Miglio M.R., Thorgeirsson S.S., Feo F. Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology 2005, 42:1310-1319.
92. Pedersen P.L., Mathupala S., Rempel A., Geschwind J.F., Ko Y.H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta 2002, 1555:14-20.
93. Piao Z., Kim H., Jeon B.K., Lee W.J., Park C. Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. Cancer 1997, 80:865-872.
94. Pulling L.C., Klinge D.M., Belinsky S.A. P16INK4a and beta-catenin alterations in rat liver tumors induced by NNK. Carcinogenesis 2001, 22:461-466.
95. Rizell M., Andersson M., Cahlin C., Hafström L., Olausson M., Lindnér P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int. J. Clin. Oncol. 2008, 13:66-70.
96. Santoni-Rugiu E., Jensen M.R., Thorgeirsson S.S. Disruption of pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-Myc and Transforming Growth Factor-α. Cancer Res. 1998, 58:123-134.
97. Sargent L.M., Dragan Y.P., Sattle G., Xu Y.H., Wiley J., Pitot H.C. Specific chromosomal changes in albumin simian virus 40 T antigen transgenic rat liver neoplasms. Cancer Res. 1997, 57:3451-3456.
98. Sargent L.M., Zhou X., Keck C.L., Sanderson N.D., Zimonjic D.B., Popescu N.C., Thorgeirsson S.S. Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am. J. Pathol. 1999, 154:1047-1055.
99. Sawaoka H., Tsuji S., Tsujii M., Gunawan E.S., Sasaki Y., Kawano S., Hori M. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab. Invest. 1999, 79:1469-1477.
100. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., Bachman M.H., Borowsky A.D., Ruebner B., Cardiff R.D., Yang Q., Bishop J.M., Contag C.H., Felsher D.W. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431:1112-1117.
101. Si M.L., Zhu S., Wu H., Lu Z., Wu F., Mo Y.Y. MiR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
102. Simile, M.M., Saviozzi, M., De Miglio, M.R., Muroni, M.R., Nufris, A., Pascale, R.M., Malvaldi, G., Feo, F., 1996. Persistent chemopreventive effect of S-adenosyl-l-methionine on the development of liver putative preneoplastic lesions induced by thiobenzamide in diethylnitrosamine-initiated rats. Carcinogenesis 17, 1533-1537.
103. Simile M.M., Banni S., Angioni E., Carta G., De Miglio M.R., Muroni M.R., Calvisi D.F., Carru A., Pascale R.M., Feo F. 5′-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J. Hepatol. 2001, 34:386-394.
104. Simile M.M., De Miglio M.R., Muroni M.R., Frau M., Asara G., Serra S., Muntoni M.D., Seddaiu M.A., Daino L., Feo F., Pascale R.M. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis 2004, 25:333-341.
105. Simile M.M., Pagnan G., Pastorino F., Brignole C., De Miglio M.R., Muroni M.R., Asara G., Frau M., Seddaiu M.A., Calvisi D.F., Feo F., Ponzoni M., Pascale R.M. Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-kB and Mat1A genes in the early stages of rat liver carcinogenesis. Carcinogenesis 2005, 26:417-427.
106. Stepanova L., Leng X., Parker S.B., Harper J.W. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 1996, 10:1491-1502.
107. Su Q., Bannasch P. Relevance of hepatic preneoplasia for human hepatocarcinogenesis. Toxicol. Pathol. 2003, 31:126-133.
108. Suchy B.K., Sarafoff M., Kerler R., Rabes H.M. Amplification, rearrangements, and enhanced expression of c-myc in chemically induced rat liver tumors in vivo and in vitro. Cancer Res. 1989, 49:6781-6787.
109. Sun M.H., Han X.C., Jia M.K., Jiang W.D., Wang M., Zhang H., Han G., Jiang Y. Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World J. Gastroenterol. 2005, 11:5931-5937.
110. Takahashi Y., Kawate S., Watanabe M., Fukushima J., Mori S., Fukusato T. Amplification of c-myc and cyclin D1 genes in primary and metastatic carcinomas of the liver. Pathol. Int. 2007, 57:437-442.
111. Tanaka Y., Hanada K., Mizokami M., Yeo A.E., Shih J.W., Gojobori T., Alter H.J. Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc. Natl. Acad. Sci. USA 2002, 99:15584-15589.
112. Teeguarden J.G., Newton M.A., Dragan Y., Pitot H.C. Genome-wide los of heterozygosity analysis of chemically induced rat hepatocellular carcinomas reveals elevated frequency of allelic imbalances on chromosomes 1, 6, 8, 11. 17, and 20. Mol. Carcinogen. 2000, 28:51-61.
113. Thomas M.B., Morris J.S., Chadha R., Iwasaki M., Kaur H., Lin E., Kaseb A., Glover K., Davila M., Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 2009, 27:843-850.
114. Tsujiuchi T., Sasaki Y., Kubozoe T., Tsutsumi M., Konishi Y., Nakae D. Alterations of the Fhit gene in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Mol. Carcinogen. 2002, 34:19-24.
115. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., Llovet J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 2007, 27:55-76.
116. Wang I.C., Chen Y.J., Hughes D., Petrovic V., Major M.L., Park H.J., Tan Y., Ackerson T., Costa R.H. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell Biol. 2005, 25:10875-10894.
117. Wierstra I., Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol. Chem. 2007, 388:1257-1274.
118. Wong C.M., Fan S.T., Ng I.O. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001, 92:136-145.
119. Yau T., Chan P., Epstein R., Poo R.T.P. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int. 2009, 29:10-17.
120. Ying L., Hofseth A.B., Browning D.D., Nagarkatti M., Nagarkatti P.S., Hofseth L.J. Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. Cancer Res. 2007, 67:9286-9293.
121. Yu M.W., Chang H.C., Liaw Y.F., Lin S.M., Lee S.D., Liu C.J., Chen P.J., Hsiao T.J., Lee P.H., Chen C.J. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J. Natl. Cancer Inst. 2000, 92:1159-1164.
122. Zavrski I., Jakob C., Kaiser M., Fleissner C., Heider U., Sezer O. Molecular and clinical aspects of proteasome inhibition in the treatment of cancer. Recent Results Cancer Res. 2007, 176:165-176.
123. Zekri A.R., Bahnassy A.A., Hafez M., El-Shehaby A.M., Sherif G.M., Khaled H.M., Zakhary N. Alterations of the fragile histidine triad gene in hepatitis C virus-associated hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2005, 20:87-94.
124. Zhang J., Peng B., Chen X. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin. Cancer Res. 2005, 11:7334-7343.